Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint

Go back to Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint

Novocure (NVCR) shares jump after trial meets primary endpoint

March 27, 2024 9:58 AM EDT

Shares of Novocure (NASDAQ: NVCR) jumped Wednesday after the company reported before the open that its phase 3 METIS clinical trial met its primary endpoint.

The company's lung cancer demonstrated the slowing in the progression of cancer to the brain in... More